Karus Therapeutics secures further financing

Southampton, UK – 4 May 2010 – Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the closing of a £0.7 million financing. Investors include IP Venture Fund, Esperante, Drummond Paris and a number of existing and new Business Angels. The investment will be used to advance the development of Karus’s KAR2581 HDAC inhibitor and […]

Karus develops new family of HDAC-6 selective inhibitors

Chilworth, UK – 18 February 2010 – Karus Therapeutics Ltd, a company engaged in the discovery and development of molecular-targeted drugs to treat inflammation and cancer, announced today it had extended its HDAC drug discovery programme to include small molecules that selectively inhibit HDAC-6, a target of emerging importance in the treatment of immune-inflammatory disorders. […]

Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases.

Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Shuttleworth SJ, Bailey SG, Townsend PA. Curr Drug Targets. 2010, 11(11), p1430-8.